CN1086437A - 用白细胞介素-4抑制人免疫缺陷病毒复制的方法 - Google Patents

用白细胞介素-4抑制人免疫缺陷病毒复制的方法 Download PDF

Info

Publication number
CN1086437A
CN1086437A CN93116434A CN93116434A CN1086437A CN 1086437 A CN1086437 A CN 1086437A CN 93116434 A CN93116434 A CN 93116434A CN 93116434 A CN93116434 A CN 93116434A CN 1086437 A CN1086437 A CN 1086437A
Authority
CN
China
Prior art keywords
hiv
cell
interleukin
replication
virus
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN93116434A
Other languages
English (en)
Chinese (zh)
Inventor
J·许瓦兹
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Sharp and Dohme LLC
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Publication of CN1086437A publication Critical patent/CN1086437A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2026—IL-4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Peptides Or Proteins (AREA)
CN93116434A 1992-08-19 1993-08-18 用白细胞介素-4抑制人免疫缺陷病毒复制的方法 Pending CN1086437A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US93213492A 1992-08-19 1992-08-19
US932,134 1992-08-19

Publications (1)

Publication Number Publication Date
CN1086437A true CN1086437A (zh) 1994-05-11

Family

ID=25461831

Family Applications (1)

Application Number Title Priority Date Filing Date
CN93116434A Pending CN1086437A (zh) 1992-08-19 1993-08-18 用白细胞介素-4抑制人免疫缺陷病毒复制的方法

Country Status (22)

Country Link
US (1) US5700461A (enExample)
EP (1) EP0656785B1 (enExample)
JP (1) JP2711182B2 (enExample)
KR (1) KR950702838A (enExample)
CN (1) CN1086437A (enExample)
AT (1) ATE163860T1 (enExample)
AU (1) AU683427B2 (enExample)
CA (1) CA2142862C (enExample)
CZ (1) CZ38095A3 (enExample)
DE (1) DE69317428T2 (enExample)
ES (1) ES2113549T3 (enExample)
FI (1) FI950696A7 (enExample)
HU (1) HUT72709A (enExample)
IL (1) IL106717A0 (enExample)
MX (1) MX9305016A (enExample)
NO (1) NO950599D0 (enExample)
NZ (1) NZ255735A (enExample)
PL (1) PL307508A1 (enExample)
SK (1) SK21295A3 (enExample)
TW (1) TW291439B (enExample)
WO (1) WO1994004179A1 (enExample)
ZA (1) ZA936018B (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU7473096A (en) * 1995-11-02 1997-05-22 Schering Corporation Continuous low-dose cytokine infusion therapy
US20040132161A1 (en) * 1998-04-20 2004-07-08 Finkel Terri H. Methods and compositions for increasing CD4lymphocyte immune responsiveness
US20050124645A1 (en) * 1998-04-20 2005-06-09 Finkel Terri H. Methods and compositions for increasing CD4lymphocyte immune responsiveness
US20030232738A1 (en) * 1998-04-20 2003-12-18 National Jewish Medical And Research Center Method and composition for increasing CD4+ T lymphocyte immune responsiveness
AU4716299A (en) * 1998-06-24 2000-01-10 Emory University Use of 3'-azido-2',3'-dideoxyuridine in combination with further anti-hiv drugs for the manufacture of a medicament for the treatment of hiv
US6734192B1 (en) 1999-08-23 2004-05-11 Mp-1 Inc. Treatment of viral infections

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4724232A (en) * 1985-03-16 1988-02-09 Burroughs Wellcome Co. Treatment of human viral infections
JPH02485A (ja) * 1987-08-03 1990-01-05 Yuu Honshiyo 新規なヒトインターロイキン４、該因子を発現させるための組換えベクター及びそのベクターにより形質転換された形質転換体
US5011829A (en) * 1989-06-02 1991-04-30 G. D. Searle & Co. Pharmaceutical composition and method of inhibiting virus
ATE133074T1 (de) * 1990-03-21 1996-02-15 Schering Corp Verwendung von il-4 zur verstärkung der immunantwort auf infektiöse antigen- herausforderungen
US5206345A (en) * 1990-08-02 1993-04-27 Fred Hutchinson Cancer Research Center Il-4 and tnf induce mab 6g10-recognized expression on bone marrow stromal cells
EP0490006B1 (en) * 1990-12-13 1994-06-22 Schering-Plough Pharmaceutical compositions for the treatment of B-cell malignancies

Also Published As

Publication number Publication date
AU683427B2 (en) 1997-11-13
FI950696A0 (fi) 1995-02-16
SK21295A3 (en) 1997-01-08
CA2142862A1 (en) 1994-03-03
DE69317428D1 (de) 1998-04-16
DE69317428T2 (de) 1998-07-02
CZ38095A3 (en) 1995-12-13
PL307508A1 (en) 1995-05-29
EP0656785B1 (en) 1998-03-11
KR950702838A (ko) 1995-08-23
WO1994004179A1 (en) 1994-03-03
US5700461A (en) 1997-12-23
ATE163860T1 (de) 1998-03-15
HU9500487D0 (en) 1995-04-28
IL106717A0 (en) 1993-12-08
EP0656785A1 (en) 1995-06-14
MX9305016A (es) 1994-02-28
JPH07506116A (ja) 1995-07-06
FI950696L (fi) 1995-02-16
ZA936018B (en) 1994-06-13
NZ255735A (en) 1997-06-24
AU5007593A (en) 1994-03-15
FI950696A7 (fi) 1995-02-16
TW291439B (enExample) 1996-11-21
NO950599L (no) 1995-02-17
HUT72709A (en) 1996-05-28
JP2711182B2 (ja) 1998-02-10
ES2113549T3 (es) 1998-05-01
CA2142862C (en) 2000-05-30
NO950599D0 (no) 1995-02-17

Similar Documents

Publication Publication Date Title
Mutter et al. Failure in generating hemopoietic stem cells is the primary cause of death from cytomegalovirus disease in the immunocompromised host.
Ahmed et al. T4+ T helper cell function in vivo: differential requirement for induction of antiviral cytotoxic T-cell and antibody responses
Koyanagi et al. In vivo infection of human T-cell leukemia virus type I in non-T cells
De Clercq Targets and strategies for the antiviral chemotherapy of AIDS
Macpherson et al. Long‐term survival and concomitant gene expression of ribozyme‐transduced CD4+ T‐lymphocytes in HIV‐infected patients
Varanasi et al. Azacytidine treatment inhibits the progression of herpes stromal keratitis by enhancing regulatory T cell function
Policard et al. Immune characterization and profiles of SARS-CoV-2 infected patients reveals potential host therapeutic targets and SARS-CoV-2 oncogenesis mechanism
Toossi et al. Activation of latent HIV-1 by Mycobacterium tuberculosis and its purified protein derivative in alveolar macrophages from HIV-infected individuals in vitro
Gerlach et al. Effects of type I interferons on Friend retrovirus infection
Burd et al. Human herpesvirus-6-associated suppression of growth factor-induced macrophage maturation in human bone marrow cultures
CN1059659A (zh) 病毒性肝炎的诊断和治疗
CN1086437A (zh) 用白细胞介素-4抑制人免疫缺陷病毒复制的方法
Rager-Zisman et al. Natural killer cells in resistance to virus-infected cells
Su et al. New sights of low dose IL‐2: Restoration of immune homeostasis for viral infection
Chiappelli et al. Virus interference in CoViD-19
Hirsch et al. Antiviral therapy
Peek et al. Evaluation of cytotoxicity and antiviral activity of recombinant human interferon alfa-2a and recombinant human interferon alfa-B/D hybrid against bovine viral diarrhea virus, infectious bovine rhinotracheitis virus, and vesicular stomatitis virus in vitro
CN1225016A (zh) 一种抗病毒和抗肿瘤药－白细胞介素－8
Natuk et al. Antiviral effect of lymphokine-activated killer cells: chemotaxis and homing to sites of virus infection
Skinner et al. Lymphokines induce specificity degradation in virus-induced cytolytic T-cell clones
Friedman Mechanisms of antiviral action of interferons
Malaguarnera et al. Interleukin-2 Plus Ribavirin Versus Interferon-α-2b Plus Ribavirin in Patients with Chronic Hepatitis C Who Did Not Respond to Previous Interferon-α-2b Treatment
CN112569250A (zh) 三氟尿苷制备hiv-1药物中的应用
Bloom et al. Interactions between interferon and cells of the immune system
CN1276730A (zh) α－干扰素和金刚胺用于治疗慢性丙型肝炎的应用

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C01 Deemed withdrawal of patent application (patent law 1993)
WD01 Invention patent application deemed withdrawn after publication